CLEXANE 2000IU ENOXAPARIN SODIUM 2000IU ANTIXA-XI ACTIVITY 0.2MG/0-2ML, SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
SODIUM 2000 IU ANTI Xa-X1
What it does
Anti is a medication that helps treat various conditions, though specific details are not provided.
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Food and Drugs Authority · fetched 2026-04-18 08:32:59 · updated 2026-10-20 04:00:05
About this medicine
Anti is a medication that helps treat various conditions, though specific details are not provided.
How it works
The exact mechanism of action is not specified, but it works to help manage certain health issues.
Who it's for
This medication may be suitable for individuals experiencing specific health conditions as determined by a healthcare provider.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: anti
Anti is a class of drugs that includes immunoglobulins, which are antibodies used in various therapeutic applications. They play a crucial role in the immune response by recognizing and neutralizing pathogens such as bacteria and viruses. Immunoglobulins can be derived from human serum or produced synthetically and are utilized in the treatment of immune deficiencies, autoimmune diseases, and certain infections.
Indications
- Primary immunodeficiency disorders
- Secondary immunodeficiency states
- Autoimmune diseases such as Guillain-Barré syndrome
- Certain infections including viral hepatitis
- Prevention of infections in immunocompromised patients
Dosage
Children: Refer to the BNF for Children for appropriate dosing information tailored to paediatric patients.
Adults: Refer to the BNF for specific dosing information as it varies based on the condition being treated.
Mechanism of action
Immunoglobulins work by binding to specific antigens on pathogens, marking them for destruction by other immune cells. This can involve neutralization of toxins, opsonization for phagocytosis, and activation of the complement system, leading to enhanced clearance of pathogens and modulation of immune responses.
Pharmacodynamics
The pharmacodynamics of immunoglobulins are characterized by their ability to modulate immune responses. They can enhance the activity of phagocytic cells, inhibit the proliferation of certain cells in the immune system, and alter the production of cytokines. The specific effects depend on the subclass of immunoglobulin and the nature of the disease being treated.
Pharmacokinetics
Immunoglobulins are typically administered intravenously or subcutaneously. They have a half-life that can vary widely depending on the specific product, ranging from several days to weeks. After administration, they distribute throughout the body, with a significant portion remaining in the vascular compartment. Metabolism occurs primarily through proteolytic degradation and clearance by the reticuloendothelial system.
Interactions
- antifungals, azoles + acalabrutinib: Severe (increases exposure)
- dronedarone + antipsychotics, second generation: Severe (increases exposure)
- mexiletine + antiarrhythmics: Severe (increases risk of torsade de pointes)
- mitotane + antiarrhythmics: Severe (decreases exposure)
- carbamazepine + antipsychotics, second generation: Severe (increases risk of myelosuppression)
- antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) + elexacaftor: Severe (decreases exposure)
- antiepileptics (carbamazepine, fosphenytoin, oxcarbazepine, phenobarbital, phenytoin, primidone) + imatinib: Severe (decreases exposure)
- iron chelators + antiepileptics: Severe (decreases absorption)
- lumacaftor + antiepileptics: Severe (decreases exposure)
- antiepileptics (fosphenytoin, phenobarbital, phenytoin, primidone) + metyrapone: Severe (decreases effects)
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.